VSTM

VerastemD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

Current thesis

The cleanest positive read-through is that AVMAPKI FAKZYNJA CO-PACK is generating real commercial revenue, with the May 2026 presentation citing about $50 million of cumulative net product revenue since launch, 400+ unique U.S. prescribers through April 2026, and management’s view that the franchise can become self-sustaining in 2H 2026 [#8-K-2026-05-07].

Posture

Defensive

Lead driver

Sentiment

What changed

Sentiment remains the lead driver in the composite, 7D delta 0.0.

What can break

Coverage is low and the peer set is loose, so the post-earnings read-through has less external validation than a higher-coverage biotech and should be treated as a monitoring view rather than a high-conviction rerating call.

Momentum

Value

Sentiment

100

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $6.75 · Bull $10.50 · Bear $3.25

Data freshness

Prices

As of 2026-06-02

Fundamentals

As of 2026-06-01 • Vendor: Data Vendor v1

Scores

As of 2026-06-02 • Model: HYBRID_IC_RP

AI Memo

As of 2026-05-08 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-06-02

Supporting evidence

What

Grade D · Defensive

Confidence Medium · Net Neutral

Target $16.57

Why

Momentum3 · Δ7d -0.7

Value41 · Δ7d +0.1

Sentiment100 · Δ7d 0.0

So what

Weak posture (Net Neutral). Prioritize risk control and patience.

Lead driver: Sentiment · See AI snapshot

Momentum

34% active weight

Current posture

7d trendFlat

Δ7d

-0.7

Δ21d

-6.6

Value

32% active weight

Current posture

7d trendFlat

Δ7d

+0.1

Δ21d

+0.2

Sentiment

100

33% active weight

Current posture

7d trendFlat

Δ7d

0.0

Δ21d

+22.5

Why this grade

Composite grade D. Momentum 3.2 / Value 41.1 / Sentiment 100.0

Fundamentals (TTM)

As of 2026-06-01

Market Cap

$368.19M

Beta

0.42

Shares Out

77.15M

P/E (TTM) · Derived

-1.3

P/S (TTM)

39.62

P/FCF (TTM) · Derived

-2.05

Rev YoY

-78.6%

EPS YoY

-126.2%

Gross Margin

+85.1%

Op Margin

-1211.4%

Net Debt

-$48.09M

Current Ratio

2.58

As of 2026-06-02 • Updated nightlySource: Internal modelMethodology